These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 37255343

  • 1. Tuberculosis in migrants: epidemiology, resistance and outcome in Milan, Italy.
    Riccardi N, Antonello RM, Ferrarese M, Saderi L, Besozzi G, Sotgiu G, Codecasa L.
    Infect Dis (Lond); 2023 Aug; 55(8):543-550. PubMed ID: 37255343
    [Abstract] [Full Text] [Related]

  • 2. Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: a cross-sectional study coordinated by Stop TB Italia Onlus.
    Riccardi N, Pontarelli A, Alagna R, Saderi L, Ferrarese M, Castellotti P, Viggiani P, Cirillo D, Besozzi G, Sotgiu G, Codecasa L, for StopTB Italia Onlus Group.
    Public Health; 2020 Mar; 180():17-21. PubMed ID: 31837610
    [Abstract] [Full Text] [Related]

  • 3. Migrations do not modify Mycobacterium tuberculosis resistance rates: a 20-year retrospective study.
    Seminari E, Monzillo V, Lombardi A, Barbarini D, Scudeller L, Schimmenti A, Muzzi A, Marone P.
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1083-1087. PubMed ID: 31980988
    [Abstract] [Full Text] [Related]

  • 4. Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.
    Nellums LB, Rustage K, Hargreaves S, Friedland JS.
    BMC Med; 2018 Feb 22; 16(1):27. PubMed ID: 29466983
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR, Balakrishna Y, Lutchminarain K, Mlisana K.
    BMJ Open; 2019 Nov 06; 9(11):e031663. PubMed ID: 31699736
    [Abstract] [Full Text] [Related]

  • 7. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.
    Chum HJ, O'Brien RJ, Chonde TM, Graf P, Rieder HL.
    AIDS; 1996 Mar 06; 10(3):299-309. PubMed ID: 8882670
    [Abstract] [Full Text] [Related]

  • 8. Impact of alcohol drinking and tobacco smoking on the drug-resistance of newly diagnosed tuberculosis: a retrospective cohort study in Shandong, China, during 2004-2020.
    Song WM, Li SJ, Liu JY, Fu Q, Xu TT, Tao NN, Zhang QY, Liu SQ, An QQ, Zhu XH, Liu Y, Yu CB, Li YF, Dong J, Li HC.
    BMJ Open; 2022 Jul 28; 12(7):e059149. PubMed ID: 35902191
    [Abstract] [Full Text] [Related]

  • 9. Contribution of rural-to-urban migration in the prevalence of drug resistant tuberculosis in China.
    Wang W, Wang J, Zhao Q, Darling ND, Yu M, Zhou B, Xu B.
    Eur J Clin Microbiol Infect Dis; 2011 Apr 28; 30(4):581-6. PubMed ID: 21174222
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Analysis of Mycobacterium tuberculosis Complex Strains Isolated from the Samples of Patients Living in Northern Syria].
    Gazel D, Çeylan K, Çalışkantürk G, Karslıgil T.
    Mikrobiyol Bul; 2023 Jul 28; 57(3):444-453. PubMed ID: 37462307
    [Abstract] [Full Text] [Related]

  • 12. Drug-resistant tuberculosis in Naples, 2008-2013.
    Del Giudice A, Mustazzolu A, Iacobino A, Perna R, Smeraglia R, Marino R, Fattorini L, Santoro G.
    Ann Ist Super Sanita; 2016 Jul 28; 52(4):603-607. PubMed ID: 27999235
    [Abstract] [Full Text] [Related]

  • 13. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC.
    JAMA; 2000 May 17; 283(19):2537-45. PubMed ID: 10815117
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy. The Italian Drug-Resistant Tuberculosis Study Group.
    Angarano G, Carbonara S, Costa D, Gori A.
    Int J Tuberc Lung Dis; 1998 Apr 17; 2(4):303-11. PubMed ID: 9559401
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K, Saini V, Dhillon R, Agarwal P.
    Indian J Tuberc; 2019 Apr 17; 66(2):247-252. PubMed ID: 31151492
    [Abstract] [Full Text] [Related]

  • 18. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S, Jo KW, Lee SD, Kim WS, Shim TS.
    Respir Med; 2017 Oct 17; 131():43-48. PubMed ID: 28947041
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antituberculosis drug-resistance surveillance as a tool for tuberculosis control programmes: a retrospective study.
    La Raja M, Screm C, Talmassons G, Pasquadibisceglie A, Pitzalis G, Pitzus E.
    Monaldi Arch Chest Dis; 1997 Oct 17; 52(5):450-4. PubMed ID: 9510665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.